STRIVERDI RESPIMAT
LABA SMI
Olodaterol · Boehringer Ingelheim
Active Medication & Mechanism
- Olodaterol hydrochloride LABA2.5 mcg per actuation
Long-acting beta2-adrenergic agonist. Selectively stimulates beta2-receptors on airway smooth muscle, increasing intracellular cAMP and producing sustained bronchodilation (~24 hours).
FDA-Approved Dosing — Strength × Indication
Strength Regimen COPDAsthma
2.5 mcg
2 puffs (5 mcg total) once daily at the same time each day → 5 mcg
FDA Approved
Long-term, once-daily maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema.
Not Approved
Striverdi is NOT indicated for asthma. LABA without ICS increases risk of serious asthma events.
All regimens shown apply to adults (≥18 years) unless otherwise noted · verify against current labelling
2.5 mcg 2 puffs (5 mcg total) once daily at the same time each day → 5 mcg
COPD FDA Approved
Long-term, once-daily maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema.
Asthma Not Approved
Striverdi is NOT indicated for asthma. LABA without ICS increases risk of serious asthma events.
All regimens shown apply to adults (≥18 years) unless otherwise noted · verify against current labelling
Not a rescue inhaler. Not for acute bronchospasm. Use a SABA.
Related Inhalers
Other LABA inhalers